talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
Published 10 months ago • 76 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
0:55
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
18:58
talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
-
5:52
talapro-1: phase ii study of talazoparib in patients with dna damage repair alterations and mcrpc
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
5:01
talazoparib plus enzalutamide shows improvement in pfs over soc in first-line hrr mcrpc
-
12:15
functions of law - video presentation pad120 group 2 kam1102f
-
1:30:47
allycon 2020: advances in precision treatment and therapies for colorectal cancer
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
9:29
implications of the fda approval of combination talazoparib & enzalutamide therapy
-
5:31
fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
1:01
choosing the correct parp inhibitor for prostate cancer
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
1:41
dr gong on the frontline use of parp inhibitors in mcrpc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
1:39
dr. howard scher on corticosteroids during treatment with enzalutamide in mcrpc
-
0:56
dr. trabulsi defines locally advanced prostate cancer
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
2:24
delaying disease progression in early, non-metastatic crpc treatment
-
0:44
dr. gomella on enzalutamide in prostate cancer
-
1:38
dr. morgan on olaparib for metastatic castration-resistant prostate cancer